NeoVax Plus Ipilimumab in Renal Cell Carcinoma
Clinical trial NCT02950766 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02950766
- Sponsor
- Patrick Ott, MD, PhD
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-03
- Primary completion
- 2027-12-31
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.